RxDoctor Payments Data

Edward Legarreta, MD

Ophthalmology · Cheektowaga, NYNPI 1942265988

Payments from drug & device makers

$3,490in general payments, 2019–2025

Across 146 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$653
  • Biotissue Holdings Inc.$488
  • Novartis$308
  • Sun Pharmaceutical Industries Inc.$267
  • Bausch & Lomb Americas Inc.$158
  • plus $353 from 8 others

What the payments were for

  • Travel & lodging$2156%
  • Food & beverage$3,27594%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,490 in reported general payments places this provider in the 70th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$75,281
Medicare patients
213
Services billed
1,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast57$73,590
LumiganBimatoprost136$67,476
RestasisCyclosporine48$64,580
Cyclosporine85$46,828
ZirganGanciclovir18$8,616
RhopressaNetarsudil Mesylate18$7,928
Alphagan PBrimonidine Tartrate17$6,762
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$5,430
Latanoprost391$3,821
RocklatanNetarsudil Mesylat/Latanoprost11$3,804
Brimonidine Tartrate21$3,799
Timolol Maleate50$2,957
MoxifloxacinMoxifloxacin Hcl94$1,728
Tobramycin-DexamethasoneTobramycin/Dexamethasone38$1,446
Prednisolone Acetate15$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$653$138,818201 claims
Bausch & Lomb Americas Inc.Xiidra, Zirgan$158$82,20675 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$83$11,73129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Cheektowaga

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →